Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 8:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 2,901 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Capsules Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Placebo Controlled Study of Atomoxetine in the Treatment of Mild to Moderate Cognitive Difficulties in Menopausal Women

NCT00611533
View directory record Official record
Conditions
Menopause, Cognitive Disturbances
Interventions
atomoxetine, placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 25, 2026, 8:37 AM EDT
Completed Phase 2 Interventional Results available

SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder

NCT00985725
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate), Matching placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
33
States / cities
Imperial, California • Los Alamitos, California • Oceanside, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 25, 2026, 8:37 AM EDT
Completed Phase 3 Interventional

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

NCT01993225
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 12.5 mg/25 mg, Placebo Capsules, AndroGel 1.62%, Placebo Gel
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
9
States / cities
Birmingham, Alabama • Mobile, Alabama • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Oct 25, 2026, 8:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Fecal Microbiota Transplant for Improvement of Metabolism

NCT02530385
View directory record Official record
Conditions
Obesity
Interventions
Placebo Capsules, FMT Capsules
Other · Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Oct 25, 2026, 8:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and PK Study of EC-18 in Healthy Subjects

NCT02496143
View directory record Official record
Conditions
Chemotherapy-induced Neutropenia
Interventions
EC-18, Placebo
Drug
Lead sponsor
Enzychem Lifesciences Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Oct 25, 2026, 8:37 AM EDT
Completed Not applicable Interventional

Key Nutrients and Mental Health

NCT03336125
View directory record Official record
Conditions
Mental Health Impairment
Interventions
Vitamin D, Placebo
Dietary Supplement
Lead sponsor
University of Bergen
Other
Eligibility
18 Years and older · Male only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Mauston, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 25, 2026, 8:37 AM EDT
Active, not recruiting Phase 2 Interventional

Statins for the Treatment of NASH

NCT04679376
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Rochester, Minnesota • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 25, 2026, 8:37 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic Health

NCT07760506
View directory record Official record
Conditions
Healthy Aging, Inflammaging, Metabolic Health, Quercetin, Coenzyme Q10
Interventions
Quercetin (dietary supplement), Coenzyme Q10, Rice Flour
Dietary Supplement
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
50 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 25, 2026, 8:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Mechanisms of Cerebrovascular Control

NCT02936687
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
NOS Inhibition, ET-1 Inhibition, NOS Inhibition Placebo, 3 Tesla MRI, Intravenous Catheter, Oral Glucose Tolerance Test, ET-1 Inhibition Placebo
Drug · Device · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 25, 2026, 8:37 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis Risk in Postmenopausal Females

NCT07365514
View directory record Official record
Conditions
Postmenopausal Osteoporosis, Gut Microbiome, Menopause
Interventions
Blackcurrant (BC) extract, Placebo
Drug
Lead sponsor
University of Connecticut
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 25, 2026, 8:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2849466 in Healthy Male Subjects

NCT01696604
View directory record Official record
Conditions
Cachexia
Interventions
GSK2849466, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 25, 2026, 8:37 AM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel

NCT01821833
View directory record Official record
Conditions
Breast Cancer, Ovarian Neoplasm, Pain
Interventions
Omega-3 fatty acid, Placebo, Paclitaxel
Dietary Supplement · Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Oct 25, 2026, 8:37 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension

NCT00817635
View directory record Official record
Conditions
Hypertension
Interventions
LCI699, Eplerenone, LCI699-matching Placebo, Eplerenone-matching Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
37
States / cities
Mobile, Alabama • Sierra Vista, Arizona • Buena Park, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 25, 2026, 8:37 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Androxal in Male Infertility

NCT02160704
View directory record Official record
Conditions
Infertility
Interventions
Enclomiphene citrate, Placebo
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 35 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Oct 25, 2026, 8:37 AM EDT
Completed Phase 2 Interventional

Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout

NCT05253833
View directory record Official record
Conditions
Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
Interventions
AR882 Dose 1, AR882 Dose 2, Allopurinol Tablet
Drug
Lead sponsor
Arthrosi Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 25, 2026, 8:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Fruit and Vegetable Juice Concentrate Effects on RBP4 and Antioxidant Capacity in Lean and Overweight 6-10 Year Old Boys

NCT00842543
View directory record Official record
Conditions
Obesity
Interventions
Fruit and Vegetable Juice Concentrate (FVJC), Placebo
Dietary Supplement
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
6 Years to 10 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Oct 25, 2026, 8:37 AM EDT
Recruiting Phase 2 Interventional

Amitriptyline for IBS-like Symptoms in Quiescent Crohn's Disease

NCT07556718
View directory record Official record
Conditions
Quiescent Crohn's Disease (CD)
Interventions
Amitriptyline, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 25, 2026, 8:37 AM EDT
Terminated Phase 3 Interventional Results available

Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02470585
View directory record Official record
Conditions
Ovarian Cancer, Ovarian Neoplasm
Interventions
Veliparib, Paclitaxel, Carboplatin, Placebo to Veliparib
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
135
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 101 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 25, 2026, 8:37 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis

NCT00646035
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
paricalcitol capsules
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
22
States / cities
Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2008 · Synced Oct 25, 2026, 8:37 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Effect of Fruit and Vegetable Concentrates on Endothelial Function in Persons With Metabolic Syndrome

NCT01224743
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Blend 1, Blend 2, Placebo
Dietary Supplement
Lead sponsor
Griffin Hospital
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Derby, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Oct 25, 2026, 8:37 AM EDT
Recruiting Phase 4 Interventional

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

NCT04781140
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
100mg SPN-812, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
48 Months to 69 Months
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
54
States / cities
Saraland, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 25, 2026, 8:37 AM EDT
Completed Phase 2 Interventional

N-Acetylcysteine and Smoking Reduction

NCT00751257
View directory record Official record
Conditions
Nicotine Dependence
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 25, 2026, 8:37 AM EDT
Recruiting Phase 2Phase 3 Interventional

MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction

NCT06191965
View directory record Official record
Conditions
Schizophrenia and Related Disorders, Mitochondrial Alteration, Cognitive Impairment
Interventions
MitoQ, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut • Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 25, 2026, 8:37 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Use of Venlafaxine in Reducing Pain in Primary Total Knee Replacement

NCT05023278
View directory record Official record
Conditions
Acute Pain, Chronic Pain, Knee Pain Chronic, Neuropathic Pain
Interventions
Venlafaxine 37.5 MG, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 25, 2026, 8:37 AM EDT